PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Neurol Neurosurg Psychiatry. 1973 June; 36(3): 354–361.
PMCID: PMC494333

Interactions of L-dopa and amantadine in patients with Parkinsonism

Abstract

Twenty-seven patients with Parkinson's disease participated in a double-blind crossover trial of L-dopa and amantadine. Each drug was given for six weeks, and six weeks were allowed to elapse between the two periods of treatment. Marked improvement occurred in patients given L-dopa first, whereas no clinical effect was observed in those patients treated first with amantadine. L-dopa was less beneficial to patients who had previously received amantadine, whereas amantadine became effective in patients who had previously taken L-dopa. The effect of pre-treatment with one drug on the therapeutic effectiveness of the other drug is reflected in changes of homovanillic acid levels in the cerebrospinal fluid.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • AGATE FJ, Jr, DOSHAY LJ, CURTIS FK. Quantitative measurement of therapy in paralysis agitans. J Am Med Assoc. 1956 Feb 4;160(5):352–354. [PubMed]
  • ANDEN NE, ROOS BE, WERDINIUS B. On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method. Life Sci. 1963 Jul;7:448–458. [PubMed]
  • Bleidner WE, Harmon JB, Hewes WE, Lynes TE, Hermann EC. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther. 1965 Dec;150(3):484–490. [PubMed]
  • Calne DB, Stern GM, Spiers AS, Laurence DR. L-dopa in idiopathic parkinsonism. Lancet. 1969 Nov 8;2(7628):973–976. [PubMed]
  • Calne DB, Stern GM, Laurence DR, Sharkey J, Armitage P. L-dopa in postencephalitic parkinsonism. Lancet. 1969 Apr 12;1(7598):744–746. [PubMed]
  • Fieschi C, Nardini M, Casacchia M, Tedone ME, Reitano M, Robotti E. Amantadine versus L-2 dopa and amatadine plus L-dopa. Lancet. 1970 Jul 18;2(7664):154–155. [PubMed]
  • Fletcher EA, Redfern PH. The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates. J Pharm Pharmacol. 1970 Dec;22(12):957–959. [PubMed]
  • Godwin-Austen RB, Frears CC, Bergmann S, Parkes JD, Knill-Jones RP. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet. 1970 Aug 22;2(7669):383–385. [PubMed]
  • Godwin-Austen RB, Tomlinson EB, Frears CC, Kok HW. Effects of L-dopa in Parkinson's disease. Lancet. 1969 Jul 26;2(7613):165–168. [PubMed]
  • Gomirato G, Perfetti C. L'associazione terapeutica L-dopa amantadina. Primi risultati in un gruppo di to Parkinsoniani. Riv Neurobiol. 1970 Jul-Sep;16(3):247–254. [PubMed]
  • Hunter KR, Stern GM, Laurence DR, Armitage P. Amantadine in parkinsonism. Lancet. 1970 May 30;1(7657):1127–1129. [PubMed]
  • Hunter KR, Stern GM, Laurence DR, Armitage P. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet. 1970 Sep 12;2(7672):566–566. [PubMed]
  • Mawdsley C. Treatment of Parkinsonism with Laevo-dopa. Br Med J. 1970 Feb 7;1(5692):331–337. [PMC free article] [PubMed]
  • Parkes JD, Calver DM, Zilkha KJ, Knill-Jones RP. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet. 1970 Feb 7;1(7641):259–262. [PubMed]
  • Schnieden H. An apparatus for measuring passive resistance to movement of the forearm in man. Br J Pharmacol. 1969 Oct;37(2):542P–543P. [PubMed]
  • Stromberg U, Svensson TH, Waldeck B. On the mode of action of amantadine. J Pharm Pharmacol. 1970 Dec;22(12):959–962. [PubMed]
  • Webster DD. Critical analysis of the disability in Parkinson's disease. Mod Treat. 1968 Mar;5(2):257–282. [PubMed]
  • Weeth JB, Shealy CN, Mercier DA. L-dopa and amantadine in the therapy of parkinsonism. Wis Med J. 1969 Nov;68(11):325–328. [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Group